Cargando…

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Wen, Xu, Tianqi, Altai, Mohamed, Oroujeni, Maryam, Zhang, Jie, Vorobyeva, Anzhelika, Vorontsova, Olga, Vtorushin, Sergey V., Tolmachev, Vladimir, Gräslund, Torbjörn, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617914/
https://www.ncbi.nlm.nih.gov/pubmed/34834389
http://dx.doi.org/10.3390/pharmaceutics13111974
_version_ 1784604621289816064
author Yin, Wen
Xu, Tianqi
Altai, Mohamed
Oroujeni, Maryam
Zhang, Jie
Vorobyeva, Anzhelika
Vorontsova, Olga
Vtorushin, Sergey V.
Tolmachev, Vladimir
Gräslund, Torbjörn
Orlova, Anna
author_facet Yin, Wen
Xu, Tianqi
Altai, Mohamed
Oroujeni, Maryam
Zhang, Jie
Vorobyeva, Anzhelika
Vorontsova, Olga
Vtorushin, Sergey V.
Tolmachev, Vladimir
Gräslund, Torbjörn
Orlova, Anna
author_sort Yin, Wen
collection PubMed
description Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1.
format Online
Article
Text
id pubmed-8617914
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86179142021-11-27 The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy Yin, Wen Xu, Tianqi Altai, Mohamed Oroujeni, Maryam Zhang, Jie Vorobyeva, Anzhelika Vorontsova, Olga Vtorushin, Sergey V. Tolmachev, Vladimir Gräslund, Torbjörn Orlova, Anna Pharmaceutics Article Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1. MDPI 2021-11-21 /pmc/articles/PMC8617914/ /pubmed/34834389 http://dx.doi.org/10.3390/pharmaceutics13111974 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yin, Wen
Xu, Tianqi
Altai, Mohamed
Oroujeni, Maryam
Zhang, Jie
Vorobyeva, Anzhelika
Vorontsova, Olga
Vtorushin, Sergey V.
Tolmachev, Vladimir
Gräslund, Torbjörn
Orlova, Anna
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
title The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
title_full The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
title_fullStr The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
title_full_unstemmed The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
title_short The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
title_sort influence of domain permutations of an albumin-binding domain-fused her2-targeting affibody-based drug conjugate on tumor cell proliferation and therapy efficacy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617914/
https://www.ncbi.nlm.nih.gov/pubmed/34834389
http://dx.doi.org/10.3390/pharmaceutics13111974
work_keys_str_mv AT yinwen theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT xutianqi theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT altaimohamed theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT oroujenimaryam theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT zhangjie theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT vorobyevaanzhelika theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT vorontsovaolga theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT vtorushinsergeyv theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT tolmachevvladimir theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT graslundtorbjorn theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT orlovaanna theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT yinwen influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT xutianqi influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT altaimohamed influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT oroujenimaryam influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT zhangjie influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT vorobyevaanzhelika influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT vorontsovaolga influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT vtorushinsergeyv influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT tolmachevvladimir influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT graslundtorbjorn influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy
AT orlovaanna influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy